TearLab (OTCMKTS: TEAR) and LightPath Technologies (NASDAQ:LPTH) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.
This table compares TearLab and LightPath Technologies’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Valuation & Earnings
This table compares TearLab and LightPath Technologies’ top-line revenue, earnings per share (EPS) and valuation.
||Earnings Per Share
LightPath Technologies has higher revenue and earnings than TearLab. TearLab is trading at a lower price-to-earnings ratio than LightPath Technologies, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for TearLab and LightPath Technologies, as reported by MarketBeat.
||Strong Buy Ratings
TearLab currently has a consensus target price of $5.75, indicating a potential upside of 1,177.78%. LightPath Technologies has a consensus target price of $2.80, indicating a potential upside of 19.15%. Given TearLab’s higher probable upside, equities research analysts plainly believe TearLab is more favorable than LightPath Technologies.
Volatility & Risk
TearLab has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500. Comparatively, LightPath Technologies has a beta of -0.66, suggesting that its share price is 166% less volatile than the S&P 500.
Insider & Institutional Ownership
12.2% of TearLab shares are held by institutional investors. Comparatively, 32.6% of LightPath Technologies shares are held by institutional investors. 12.0% of TearLab shares are held by company insiders. Comparatively, 12.7% of LightPath Technologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
LightPath Technologies beats TearLab on 9 of the 12 factors compared between the two stocks.
TearLab Company Profile
TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor’s office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.
LightPath Technologies Company Profile
LightPath Technologies, Inc. is a manufacturer and integrator of families of precision molded aspheric optics, fiber-optic collimator, GRADIUM glass lenses and other optical materials used to produce products that manipulate light. The Company designs, develops, manufactures and distributes optical components and assemblies utilizing the optical processes and manufacturing technologies. The Company also performs research and development for optical solutions for the traditional optics markets and communications markets. The Company’s products are incorporated into a range of applications by its customers in various industries, including defense products, medical devices, laser aided industrial tools, automotive safety applications, barcode scanners, optical data storage, hybrid fiber coax datacom, telecommunications, machine vision and sensors.
Receive News & Ratings for TearLab Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TearLab Corporation and related companies with MarketBeat.com's FREE daily email newsletter.